WNK2 and neoplasm: Immunotherapy by checkpoint inhibitors or whole tumor vaccines might be less affected by this type of resistance, although patients who show acquired resistance to anti-mitogen-activated protein kinases targeted therapy often develop cross-resistance to immunotherapy.16